|

TORL-5-700 at MTD/RP2D in combination with another agent Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • TORL Biotherapeutics, LLC1

Indications

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma1
  • Cancer1

Santa Monica, California1 trial

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

UCLA

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.